secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210428
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics Q1 net loss $15M; Phase 2 PV trial on track for August 2026 topline
--------------------------------------------------------------------------------

- Net loss of $15.0M ($0.11 per share) vs $28.5M ($0.20) a year ago; revenue from AstraZeneca collaboration $0.4M.
- Cash, cash equivalents & short-term investments at $70.1M as of March 31, 2026.
- R&D expenses fell to $9.1M from $20.8M, primarily due to zerlasiran Phase 3 readiness completed in 2025.
- Phase 2 SANRECO trial of divesiran for polycythemia vera ongoing; topline results expected August 2026.
- Phase 1 abstracts for divesiran (EHA) and SLN312/AZD1705 (EAS) accepted for upcoming congress presentations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/0001193125-26-210428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/sln-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer